Search Patents
  • ANTIBODY SPECIFIC FOR SARS-COV-2 RECEPTOR BINDING DOMAIN AND THERAPEUTIC METHODS
    Publication number: 20230382978
    Abstract: Antibodies against coronavirus receptor binding domain (SARS-CoV-2) are provided. The antibodies have neutralizing activity against coronaviruses and their activity. The anti-coronavirus receptor binding domain antibodies may be used in therapeutic treatment in patients with coronavirus infections and/or conditions associated with coronavirus infection.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 30, 2023
    Inventors: Kaitlyn Noelle SADTLER, Matthew James MEMOLI
  • Serine protease inhibitor for treating coronavirus infection
    Patent number: 11918560
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: March 5, 2024
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20220378815
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 1, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • COMPOSITION FOR PREVENTING OR TREATING COVID-19, INCLUDING GOLD NANOPARTICLE AS ACTIVE INGREDIENT
    Publication number: 20210308180
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing coronavirus infection (COVID-19), containing a gold nanoparticle. In the present invention, the gold nanoparticles hinder the morphological change of a coronavirus protein to block the entry of the coronavirus protein into cells, resulting in prevention or treatment of the coronavirus infection (COVID-19).
    Type: Application
    Filed: July 15, 2020
    Publication date: October 7, 2021
    Inventor: Chur CHIN
  • Serine protease inhibitor for treating coronavirus infection
    Patent number: 11045453
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: June 29, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • PD-1-based vaccines against coronavirus infection
    Patent number: 12018063
    Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: June 25, 2024
    Assignee: Versitech Limited
    Inventors: Zhiwei Chen, Kwok Yung Yuen, Honglin Chen, Yik Chun Wong, Li Liu
  • SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20240350461
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: January 30, 2024
    Publication date: October 24, 2024
    Inventors: Dror Ben-Asher, Reza Fathi
  • Prefusion coronavirus spike proteins and their use
    Patent number: 11964010
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 23, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Prefusion coronavirus spike proteins and their use
    Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • CORONAVIRUS VACCINE AND METHODS OF USE THEREOF
    Publication number: 20210393769
    Abstract: An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.
    Type: Application
    Filed: June 8, 2021
    Publication date: December 23, 2021
    Inventor: Davinder Gill
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Compositions and methods for detecting severe acute respiratory syndrome coronavirus
    Patent number: 7129042
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: October 31, 2006
    Assignees: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
  • HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230312689
    Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 5, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, The University of Tokyo
    Inventors: Shuzo MATSUSHITA, Yu KAKU, Takeo KUWATA, Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI
  • STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION
    Publication number: 20240299481
    Abstract: In an embodiment, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided. According to an embodiment of the present invention, a preparation for treatment of a novel coronavirus infection comprises Cepharanthine, Isotetrandrine, Cycleanine, and Berbamine. A preparation for treatment of a novel coronavirus infection is for treatment of an infection caused by the novel coronavirus mutant strain. According to an embodiment of the present invention, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Inventors: Koichi WATASHI, Wakana SASO, Toru TERASHIMA
  • Adjuvants for vaccines
    Patent number: 5047238
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: March 24, 1988
    Date of Patent: September 10, 1991
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • Compositions and methods for detecting a non plus-stranded RNA virus
    Patent number: 7846655
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: December 7, 2010
    Assignee: Diagnostic Hybrids, Inc.
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus
    Publication number: 20110223659
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: December 7, 2010
    Publication date: September 15, 2011
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Inactivated canine coronavirus vaccine
    Patent number: 4567042
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: June 7, 1984
    Date of Patent: January 28, 1986
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • METHODS AND COMPOSITIONS FOR TREATING A CORONAVIRUS INFECTION
    Publication number: 20240116996
    Abstract: The disclosure provides methods of treating an infection by a coronavirus with a fibroblast growth factor (“FGF”). Also provided herein are FGFs for treating an infection by a coronavirus and their use in the manufacture of a medicament for treating an infection by a coronavirus.
    Type: Application
    Filed: April 5, 2022
    Publication date: April 11, 2024
    Inventor: Seth P. FINKLESTEIN
  • Protease Inhibitors for Treatment or Prevention of Coronavirus Disease
    Publication number: 20230192660
    Abstract: Provided are protease inhibitor compounds that find use in treating or preventing coronavirus disease. In some embodiments, the coronavirus disease is COVID-19. Also provided are compositions and kits comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus disease. Methods of assessing inhibition of coronavirus protease activity by an agent are also provided.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 22, 2023
    Inventors: Michael Z. Lin, Xinzhi Zou, Michael Westberg Soerensen, Lin Ning, Yichi Su
Narrow Results

Filter by US Classification